New antibody drug shows promise for blocking asthma attacks
NCT ID NCT00983658
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase II trial tested a drug called huMAb OX40L in 29 adults with mild allergic asthma. The drug is an antibody designed to block a protein that triggers allergic reactions in the airways. Researchers measured whether it could prevent breathing problems caused by allergens, compared to a placebo.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- huMAb OX40L (a lab-made antibody that blocks a protein involved in allergic reactions)
- What this could lead to
- If it works, this could point toward a new treatment to control asthma attacks triggered by allergens.
- What could go wrong
- This is a small, early-phase trial with only 29 people. The drug may not work better than placebo, and side effects are still being studied.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ASTHMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can tracking severe asthma over time unlock better treatments?
- Can pressurized breathing boost mucus clearance in lung disease?
- Can a simple breathing test unlock the secrets of chronic cough?
- Can a Breath-Activated inhaler match the standard for asthma control?
- Can a School-Home program tame childhood asthma?
- Could everyday supplements shield your lungs?